Company intelligence / Profile preview

Rui Therapeutics

Guangdong Sheng, Chinaruitherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Rui Therapeutics has reported the world's first clinical trial data for CAR-NK treatment of lupus, showing deep remission in severe SLE patients after infusion of their universal/off-the-shelf CAR-NK product KN5501. Early IIT trials have demonstrated excellent safety and tumor cell clearance effects for their lead pipeline products. Additional programs are recruiting or preparing for IND submission.

Therapeutic areas: OncologyRare DiseasesImmunologyNeurology
Modalities: CAR-NK cell therapySingle-base gene editingiPSC (induced pluripotent stem cell) technology
Industry: Biotech

Drug pipeline

9 assets

KN5501

8 more assets in the full pipeline.

Partnerships

Clinical collaborations with Shanghai Changhai Hospital and Affiliated Hospital of Jiangsu UniversityChangshu No. 2 People's Hospital as a trial site sponsor/collaborator

Beyond the preview

Go deeper on Rui Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rui Therapeutics.